Rheumatologists Sharpen Differentiation Across the SLE Pipeline as Late-Stage Assets Crystallize into More Defined Clinical Roles, According to Spherix Global Insights
Nearly half of US rheumatologists expect Gazyva to meaningfully reshape SLE treatment pathways, while CAR T-cell therapy is viewed as applicable to only a small, refractory subset of patients EXTON, PA, January 20, 2026 – Updated findings from the Q4 2025 Market Dynamix™: SLE, Pipeline Refresh reveal a maturing and increasingly stratified development landscape, as US rheumatologists move from broad enthusiasm toward more selective, indication-driven […]
Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift. EXTON, PA., January 14, 2026 — Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveals growing use of subcutaneous (SC) PD-1 therapies alongside expectations for an eventual shift toward biosimilars across non-small cell lung cancer […]
Spherix Global Insights Reveals Unmet Need Driving Interest in Emerging Therapies for Thyroid Eye Disease
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in 2026 EXTON, PA, November 12, 2025 — New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED), physicians emphasize ongoing unmet needs—particularly […]